3 Halpin DMG. Defining COPD in the 21st century. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the
21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 30–44.
4 Agusti A, Faner R. A new understanding of the natural history of COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 45–62.
5 Khan MI, Khan MMKS, Mannino DM. The new epidemiology of COPD. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 63–80.
6 Maeda T, Dransfield MT. Cardiac comorbidity and COPD: chance or consequence? In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 81–99.
7 Devulder JV, Donnelly LE. Mechanisms and mediators of disease. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 100–117.
8 Tiew PY, Chotirmall SH. The microbiome and COPD. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in
the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 118–134.
9 Allinson JP. Chronic bronchitis revisited. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st
Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 135–148.
10 Beech A, Singh D. Eosinophils and COPD. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st
Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 149–167.
11 Fortis S, Comellas AP, Hoffman EA. Advances in the characterisation of COPD using quantitative imaging. In:
Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European
Respiratory Society, 2024 pp. 168–184.
12 Milne S, Tonga KO, Eddy RL, et al. New physiological measurements in COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 185–203.
13 Vestbo J, Vogelmeier C. Guidelines and strategies of management. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 204–211.
14 van den Berge M, Beghé B, Lahousse L, et al. Current pharmacotherapy of COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 212–232.
15 Flynn CA, Aung H, Greening NJ, et al. The future drug treatment of COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 233–254.
16 Singh SJ, Daynes E, Sooronbaev TM. The future of pulmonary rehabilitation in COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 255–266.
17 Finney LJ, MacLeod M, Wedzicha JA. New insights into the pathophysiology and epidemiology of COPD
exacerbations. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st Century (ERS Monograph).
Sheffield, European Respiratory Society, 2024 pp. 267–282.
18 Baraldi F, Barrecheguren M, Papi A, et al. Managing exacerbations of COPD: how much progress have we made?
In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield,
European Respiratory Society, 2024 pp. 283–296.
19 Herkenrath S, Matthes S, Randerath W. Noninvasive ventilation in COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 297–312.
20 Tonkin J, Conway FM, Shah PL. Lung volume reduction for emphysema. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 313–324.
21 Wedzicha JA, Allinson JP, Calverley PMA. COPD at a tipping point. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 325–333.
Disclosures: J.A. Wedzicha reports receiving funding direct to Imperial College from Boehringer Ingelheim,
AstraZeneca and GSK, outside the submitted work. J.A. Wedzicha is an advisor for the Global Initiative for
Obstructive Lung Disease (GOLD). J.P. Allinson reports receiving the following, outside the submitted work: grants
or contracts from Asthma UK and Lung UK payment or honoraria for lectures, presentations, speakers’ bureaus,
manuscript writing or educational events from AstraZeneca and support for attending meetings and/or travel from
AstraZeneca. J.P. Allinson is an unpaid member of the ATS Publications Policy Committee. P.M.A. Calverley reports
receiving grants, personal fees and non-financial support from pharmaceutical companies that make medicines to
treat respiratory disease. This includes reimbursement for educational activities and advisory work, and support to
attend meetings.
https://doi.org/10.1183/2312508X.10035423 xiii
21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 30–44.
4 Agusti A, Faner R. A new understanding of the natural history of COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 45–62.
5 Khan MI, Khan MMKS, Mannino DM. The new epidemiology of COPD. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 63–80.
6 Maeda T, Dransfield MT. Cardiac comorbidity and COPD: chance or consequence? In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 81–99.
7 Devulder JV, Donnelly LE. Mechanisms and mediators of disease. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 100–117.
8 Tiew PY, Chotirmall SH. The microbiome and COPD. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in
the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 118–134.
9 Allinson JP. Chronic bronchitis revisited. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st
Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 135–148.
10 Beech A, Singh D. Eosinophils and COPD. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st
Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 149–167.
11 Fortis S, Comellas AP, Hoffman EA. Advances in the characterisation of COPD using quantitative imaging. In:
Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European
Respiratory Society, 2024 pp. 168–184.
12 Milne S, Tonga KO, Eddy RL, et al. New physiological measurements in COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 185–203.
13 Vestbo J, Vogelmeier C. Guidelines and strategies of management. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 204–211.
14 van den Berge M, Beghé B, Lahousse L, et al. Current pharmacotherapy of COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 212–232.
15 Flynn CA, Aung H, Greening NJ, et al. The future drug treatment of COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 233–254.
16 Singh SJ, Daynes E, Sooronbaev TM. The future of pulmonary rehabilitation in COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 255–266.
17 Finney LJ, MacLeod M, Wedzicha JA. New insights into the pathophysiology and epidemiology of COPD
exacerbations. In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st Century (ERS Monograph).
Sheffield, European Respiratory Society, 2024 pp. 267–282.
18 Baraldi F, Barrecheguren M, Papi A, et al. Managing exacerbations of COPD: how much progress have we made?
In: Wedzicha JA, Allinson JP, Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield,
European Respiratory Society, 2024 pp. 283–296.
19 Herkenrath S, Matthes S, Randerath W. Noninvasive ventilation in COPD. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 297–312.
20 Tonkin J, Conway FM, Shah PL. Lung volume reduction for emphysema. In: Wedzicha JA, Allinson JP,
Calverley PMA, eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 313–324.
21 Wedzicha JA, Allinson JP, Calverley PMA. COPD at a tipping point. In: Wedzicha JA, Allinson JP, Calverley PMA,
eds. COPD in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 325–333.
Disclosures: J.A. Wedzicha reports receiving funding direct to Imperial College from Boehringer Ingelheim,
AstraZeneca and GSK, outside the submitted work. J.A. Wedzicha is an advisor for the Global Initiative for
Obstructive Lung Disease (GOLD). J.P. Allinson reports receiving the following, outside the submitted work: grants
or contracts from Asthma UK and Lung UK payment or honoraria for lectures, presentations, speakers’ bureaus,
manuscript writing or educational events from AstraZeneca and support for attending meetings and/or travel from
AstraZeneca. J.P. Allinson is an unpaid member of the ATS Publications Policy Committee. P.M.A. Calverley reports
receiving grants, personal fees and non-financial support from pharmaceutical companies that make medicines to
treat respiratory disease. This includes reimbursement for educational activities and advisory work, and support to
attend meetings.
https://doi.org/10.1183/2312508X.10035423 xiii